CAR-T Cell Funding Market Size, Share Global Analysis Report, 2025 – 2034

Industry Insights

[221+ Pages Report] According to Facts & Factors, the global CAR-T cell funding market size was valued at USD 42.42 billion in 2024 and is predicted to surpass USD 124.85 billion by the end of 2034. The CAR-T cell funding industry is expected to grow by a CAGR of 11.40% between 2025 and 2034.

Market Overview

CAR T-cell therapy refers to immunotherapy in which these cells are extracted from the patient’s body and reintroduced after genetically modifying them. CAR T-cell funding covers various activities like research and development, clinical trials, manufacturing, and commercialization.

Different types of CAR T-cell funding exist, including non-profit, venture capital, corporate investments, and public financing. CAR T-cell therapy is a highly personalized therapy that is quite expensive, but funding improves its accessibility and reduces therapy costs.

Key Insights

• As per the analysis shared by our research analyst, the global CAR-T cell funding market size is estimated to grow annually at a CAGR of around 11.40% over the forecast period (2025-2034).
• In terms of revenue, the global CAR-T cell funding market size was valued at around USD 42.42 billion in 2024 and is projected to reach USD 124.85 billion by 2034.
• Breakthroughs in clinical results are driving the growth of the global CAR-T cell funding market.
• Based on the end-users, the contract research organizations segment is growing at a high rate and is projected to dominate the global market.
• Based on funding source type, the venture capital segment is anticipated to grow with the highest CAGR in the global market.
• Based on the investment trends, the early-stage investment segment is projected to swipe the largest market share.
• Based on region, North America is expected to dominate the global market during the forecast period.

Growth Drivers

• Breakthroughs in clinical results are driving the growth of the global market.

Several innovative CAR T-cell therapies like Yescarta and Kymriah have emerged as the most successful cancer treatments, which is increasing the confidence of investors. Such therapies also have low remission rates.

Therefore, these require late-stage investments, which are further likely to support the market's growth. The rising prevalence of cancer and multiple myeloma is anticipated to fuel the development of the industry.

However, such growing incidents are increasing the burden on the healthcare sector, further pushing the pharma and biotech companies to develop more curative treatments. The growing public funding from agencies like Horizon Europe and NIH helps support early and translational research. It will likely revolutionize the global CAR-T cell funding market in the coming years.

Biotech and big pharma startups attract significant VC investments because of their growing focus on next-gen CAR T platforms.

The reimbursement policies worldwide are increasing the commercial viability of CAR T-cell therapies, which is also expected to foster developments in the market. For instance, NIH in 2024 said to offer a $200 million grant for initiating research into advanced cell therapies.

Restraints

• High cost of therapy is likely to hinder the growth of the global market.

CAR T-cell therapy is quite expensive compared to other available solutions. Also, the complexities in manufacturing and logistics are further restricting people from investing in the market.

Moreover, the growing demand for personalized autologous CAR T therapy makes large-scale production difficult. Therefore, such a landscape is expected to negatively impact the growth of the CAR-T cell funding industry.

Opportunities

• Expanding applications beyond oncology is fostering the growth of the global market.

The emerging studies show CAR T-cell therapies' effects on autoimmune diseases, which is anticipated to foster growth opportunities in the global CAR-T cell funding market.

However, this potential diversification of the market is attracting investors and is likely to expand rapidly in the coming years. The ongoing collaborations between CDMOs and biotech companies are further expected to revolutionize the market.

However, strategic investors are coming up with long-term investments in CAR T-cell technology, which is also expected to support the market's growth.

The growing pipeline for clinical trials globally, particularly for solid tumors and hematology, is likely to further broaden the pipeline, which drives investments in multiple developmental stages.

Challenges

• Regulatory landscape is a big challenge in the global market.

The regulatory complexities in approving the CAR T-cell therapy are a big challenge in the CAR-T cell funding industry. Navigating the global regulatory framework increases the overall cost and causes delays, thereby negatively impacting the industry's growth in the coming years.

Report Scope

Segmentation Analysis

The global CAR-T cell funding market can be segmented into end-users, funding source types, investment trends, and regions.

On the basis of end-users, the market can be segmented into outpatient surgery centers, contract research organizations, research and academic institutions, pharmaceutical companies, and others.

The contract research organizations segment is likely to account for the largest share of the CAR-T cell funding industry during the forecast period. The rising complexity in the cell and gene therapy trials is one of the primary reasons for the high growth rate of the segment.

CAR T-cell therapy is more complex than traditional drugs, and therefore, companies require CROs to manage complex trials. The globalization of clinical trials is also strengthening the growth of the segment. The rising incidence of rare diseases encourages drug developers to increase clinical trials across multiple geographies.

Also, there is a rising trend of outsourcing by biotech pharma, which is another emerging reason for the high growth rate of the segment. This outsourcing is mainly because of the lack of resources for trial executions. There is a recent boom in demand for full-service CROs, which are offering complete packages ranging from clinical development to post-marketing surveillance, which is also fostering developments in the segment.

On the basis of funding source type, the market can be segmented into corporate investments, public funding, venture capital, and others. Venture capital is expected to be the fastest-growing segment in the global CAR-T cell funding market during the forecast period.

Venture capitalists are aggressively investing in startups that are working towards developing allogeneic therapies and next-generation platforms, which is a major reason for the high growth rate of the segment. There is a recent surge in biotech startups, which are further likely to gather more investments from venture capital as they prefer to invest in high-risk, high-reward opportunities.

Moreover, CAR-T developers need quick funding, which can only be facilitated through VC funding because it offers rapid access to capital. Venture capitals boost early-phase research and clinical development, which is also likely to revolutionize the market in the coming years.

On the basis of investment trends, the market can be segmented into strategic investments, later-stage investments, and early-stage investments. The early-stage investment segment is likely to dominate the CAR-T cell funding industry during the forecast period.

The fast proliferation of biotech startups, particularly for allogeneic CAR-T and dual-target CARs, is emerging as a strong factor fueling the segment's growth.

Investors are highly willing to fund high-risk, high-reward ventures, particularly in the CGT space, because of the recent success of innovative and novel therapies. Early-stage rounds largely get more funding from VCs and angel investors.

Many incubators and government bank innovation programs support early-stage CGT ventures, which are also likely to foster developments in the segment. Many preclinical models have a lower initial cost, therefore encouraging more small firms to get early funding.

Regional Analysis

• North America is anticipated to dominate the global market.

North America accounts for the largest share of the global CAR-T cell funding market during the forecast period. The United States dominates the market in North America because it is home to the world's most successful research institutions, like Harvard and MD Anderson.

Also, the favorable regulatory landscape in the US is expected to bring huge investments into the market. Canada also holds a majority of shares in the North American market because of the rising research collaboration of companies with US institutions.

Companies in North America are working on AI-powered CAR design, which is garnering the interest of investors and is likely to revolutionize the growth of the regional market. The early-stage investments are booming in North America because phase 1 clinical trials attract high-risk investors.

Many leading market players are likely to widen the scope of the regional market. However, the strategic investments have already helped North America strengthen its global market position.

Asia-Pacific is also projected to experience substantial growth in the coming years because of numerous factors. However, one of the leading reasons for the high growth rate of the regional market is the increasing incidence of cancer in APAC.

Also, the supportive regulatory framework is expected to positively influence the regional market's growth. China holds the majority of shares in the Asia-Pacific market because of the increasing number of clinical trials in the region.

Also, Japan is emerging as the fastest-growing country because of better reimbursement policies and national insurance. South Korea is likely to contribute immensely towards the growth of the market because of increasing investments in biotech infrastructure and advanced therapies.

In addition, India is focusing on developing cost-effective CAR T solutions, which are also likely to support the spectacular rise of the regional market in the coming years.

Competitive Analysis

The key players in the global CAR-T cell funding market include:

• GSK plc.
• Sorrento Therapeutics Inc.
• Sangamo Therapeutics
• Merck & Co. Inc.
• Bluebird Bio Inc.
• JW Therapeutics (Shanghai) Co. Ltd.
• Johnson & Johnson Services Inc.
• Gilead Sciences Inc.
• Novartis AG
• Bristol-Myers Squibb Company

For instance, UVM Cancer Center revealed a new product of CAR-T cell treatment in Vermont, US, in 2023. It is an exclusive treatment therapy for patients suffering from blood cancer.

The global CAR-T cell funding market is segmented as follows:

By End-Users Segment Analysis

• Outpatient Surgery Centers
• Contract Research Organizations
• Research And Academic Institutions
• Pharmaceutical Companies
• Others

By Funding Source Types Segment Analysis

• Corporate Investments
• Public Funding
• Venture Capital
• Others

By Investment Trends Segment Analysis

• Strategic Investments
• Later-Stage Investments
• Early-Stage Investments

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America